TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy: EGFR mutated non-small cell lung cancer IV patients treated with osimertinib - Roeper, Julia; Christopoulos, Petros; Falk, Markus; Heukamp, Lukas; Tiemann, Markus; Stenzinger, Albrecht; Thomas, Michael; Griesinger, Frank (Translational Lung Cancer Research, 2022)
Gesehen am 14.02.2022